Navigation Links
Intra-Cellular Therapies Announces Positive Results with ITI-002 in Pre-Clinical Models of Parkinson's Disease
Date:10/1/2010

bidly with dementia and excessive day time sleepiness. We believe that ITI-002 will be uniquely effective in treating these non-motor complications that are associated with Parkinson's disease."

ABOUT ITI-002

ITI-002 is a unique, orally available, investigational drug being developed for the treatment of motor and non-motor impairments accompanying Parkinson's disease and other neurologic and neuropsychiatric disorders, including schizophrenia and Alzheimer's disease.

ITI-002 potently inhibits the PDE1 enzyme in a competitive manner with sub-nanomolar affinity for this subfamily. This compound is very selective for the PDE1 subfamily relative to other PDE subfamilies. ITI-002 has no significant off target activities at other enzymes, receptor or ion channels.

PDE Type I – PDE enzymes hydrolyze and inactivate cyclic nucleotides (cAMP and cGMP) in the brain.  Eleven classes of PDE enzymes with distinct tissue distributions, cyclic nucleotide selectivity, and regulatory factors are known.  The PDE1 family of enzymes, including PDE1A, PDE1B, and PDE1C isoforms, are calcium/calmodulin-dependent, dual-function (cAMP/cGMP) PDEs that are expressed at high levels in mammalian brain. This enzyme subfamily has little influence on basal nucleotide activity and only becomes active under stimulated conditions.  This "on demand" character distinguishes PDE1 from all other PDE family members. PDE1 is enriched in the striatal medium spiny neurons that lose dopamine input in Parkinson's disease and controls the responsiveness of striatal neurons to dopamine. Intra-Cellular Therapies has shown that orally available, small molecule inhibitors of PDE1 restore dopamine signaling in striatal neurons and potentiate the level of motor correction in Parkinson's disease.

About Parkinson's Disease - Parkinson's disease is a progressive, neurodegenerative disease. The prevalence of Parkinson's disease increases with a
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
2. Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies and Advances Phase III Plans for cat Allergy T-Cell Vaccine
3. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
4. Vital Therapies Expands SILVER Trial to Saudi Arabia
5. Prometheus and Tarrot Laboratories Collaborate to Identify Markers Associated With Response to Anti-TNF Therapies in Crohns Disease
6. PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies
7. US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research
8. NeoStem to Receive $700,000 from the U.S. Armys Medical Research and Materiel Command to Advance Adult Stem Cell Therapies in Treating Traumatic Wounds
9. New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting
10. ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis
11. 5th Annual Summit to Feature New Stem Cell Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... DUBLIN , June 18, 2013 /PRNewswire/ ... http://www.researchandmarkets.com/research/4b8vj2/injectable_drug ) has announced the addition of ... Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables ... Free & Auto Injectors] & Therapeutics [Diabetes ... report to their offering. ...
(Date:6/18/2013)... Though health care jobs continued to be added ... Labor Statistics -- the increase was far below the calendar ... care jobs were added in home health care and outpatient ... jobs. Overall, the U.S. unemployment rate stayed flat at 7.6 ... that a total of just over 36,000 job cuts were ...
(Date:6/18/2013)... Port Monmouth, NJ (PRWEB) June 18, 2013 ... for the AdWords advertising platform. As this directly impacts ... this to be the one of the most sweeping updates ... at Core and More Technologies recently posted a very ... not initially set a ‘must-have’ upgrade date for enhanced ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 Kitware ... today announces a new Fast-Track award from the U.S. ... design-analysis environment (IDAE) for the nuclear power industry. , ... for more than 30 years, but the United States’ ... remarkable gains in power plant utilization through improved refueling, ...
Breaking Biology Technology:Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 2Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 3MedZilla Employment Report for June 2013 -- Jobs in Health Care Grow, But at Slower Pace 2MedZilla Employment Report for June 2013 -- Jobs in Health Care Grow, But at Slower Pace 3Core and More Technologies Helps Organizations Migrate to Google’s Enhanced Campaign Structure 2Core and More Technologies Helps Organizations Migrate to Google’s Enhanced Campaign Structure 3Kitware to Develop an Open-Source HPC Design-Analysis Environment for Nuclear Energy Research 2
... Jan. 23, 2012 Novus International Inc., a leading ... and Verenium Corporation (Nasdaq: VRNM ), a ... commercialization of high-performance enzymes, today announced the selection of ... the two companies, strategic collaboration to advance ...
...   NeoStem, Inc. (NYSE Amex: NBS ) ... focus on cell-based therapeutic development, today announced that its Chief ... 2 clinical trial for AMR-001 for preservation of heart ... of its subsidiary, Progenitor Cell Therapy, LLC , have ...
... Jan. 23, 2012   BioLife Solutions , Inc. (OTCBB: ... hypothermic storage and cryopreservation freeze ... three additional key opinion leaders in the biobanking ... markets have joined the Company,s Scientific Advisory ...
Cached Biology Technology:First Product Candidate Moving Toward Commercialization as Result of Novus International and Verenium Collaboration 2First Product Candidate Moving Toward Commercialization as Result of Novus International and Verenium Collaboration 3First Product Candidate Moving Toward Commercialization as Result of Novus International and Verenium Collaboration 4First Product Candidate Moving Toward Commercialization as Result of Novus International and Verenium Collaboration 5Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease 2Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease 3Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease 4BioLife Solutions Adds Clinical and Commercialization Experts to Scientific Advisory Board 2BioLife Solutions Adds Clinical and Commercialization Experts to Scientific Advisory Board 3BioLife Solutions Adds Clinical and Commercialization Experts to Scientific Advisory Board 4BioLife Solutions Adds Clinical and Commercialization Experts to Scientific Advisory Board 5
(Date:6/17/2013)... JOLLA, CA June 17, 2013 An international ... (TSRI), the Howard Hughes Medical Institute and Albert Einstein ... highly promising new anti-tuberculosis compound that attacks the tuberculosis ... represent an effort to help solve one of the ... TB and its dangerous drug-resistant strains," said Peter G. ...
(Date:6/17/2013)... 17, 2013 As mobile devices, smartphones ... secure them grows exponentially, and biometric authentication offers ... Heavy Reading Insider ( www.heavyreading.com/mobile-networks ), ... ( www.heavyreading.com ). Biometrics Offer ... for biometric authentication on smartphones, analyzing the most ...
(Date:6/17/2013)... and Entrepreneurship will be the topics under discussion ... June. For the third consecutive year, this will ... sharing of experiences among members of Academy, Business, ... students. Confirmed speakers: Elisa Martn Garijo (IBM South ... Tree) and Mary O,Donovan (Hovione), among others. E3 ...
Breaking Biology News(10 mins):New compound excels at killing persistent and drug-resistant tuberculosis 2New compound excels at killing persistent and drug-resistant tuberculosis 3New compound excels at killing persistent and drug-resistant tuberculosis 4Biometric Authentication Provides Better Mobile Device Security, Heavy Reading Finds 2Biometric Authentication Provides Better Mobile Device Security, Heavy Reading Finds 3'E3 Forum -- Education, Employment & Entrepreneurship on a Global context' 2
... functions is largely based on our family,s genetic makeup, according ... published in the international publication the Journal of Neuroscience ... how ,cost-efficient, our brain network wiring is, shedding light on ... Alex Fornito from the Melbourne Neuropsychiatry Centre at the University ...
... the important first rung of the food web each spring ... to its advantage, according to the first published findings about ... algae as a kind of antifreeze against temperatures well below ... channels and pores in ice that are hospitable to itself ...
... bugs, originally from Asia, were first detected in Pennsylvania ... and vegetables and invading homes in many parts of ... entomologists from the eastern U.S. and Canada will converge ... brown marmorated stink bug plague during the 82nd Annual ...
Cached Biology News:Better brain wiring linked to family genes 2Algal antifreeze makes inroads into ice 2Stink bug experts gather in Pennsylvania to address growing problem 2
Rabbit polyclonal to Staphylococcus Enterotoxin A (HRP) ( Abpromise for all tested applications)....
... Novexin offers bespoke, cost-effective solutions for complex protein processing ... expertise and experience to help you develop a solution ... , ... transfer all methodology to ...
... is a highly scalable analysis platform ... in a workgroup or an enterprise ... 40 leading pharmaceutical, biotechnology, academic and ... streamlines genomics research at large and ...
... LC Sciences provides a genome-wide microRNA ... and proprietary probe design, which enable highly ... (1-3). We have standard arrays for mature ... latest version of the Sanger miRBase database ...
Biology Products: